Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer

Faisal A. Siddiqui, Katelyn M. Atkins, Brian S. Diggs, Charles Thomas, John Hunter, James Dolan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background: Patients treated with neoadjuvant chemoradiotherapy (NAC) followed by esophagectomy are more likely to have negative margins at resection, be downstaged, and have improved overall survival (OS). The specific aim of this study was to analyze OS outcomes using NAC followed by esophagectomy at a single, tertiary care academic medical center. Methods: We retrospectively analyzed 106 patients that underwent NAC with platinum-based chemotherapy plus 5-fluorouracil (5-FU) or capecitabine followed by esophagectomy from September 1996 to May 2011. OS was analyzed by the Kaplan Meier method. Results: Initial staging determined that of 106 patients, 62% had stage III (n=66), 31% stage II (n=33), and 7% had stage I disease (n=7). Following NAC, 92.5% (n=98) were resected with negative (R0) margins and pathologic staging revealed 59% (n=62) were downstaged, 9% (n=10) were upstaged, and 32% (n=34) remained at the same stage. A pathologic complete response (pCR) was achieved in 29% (n=31) of the cohort. Median OS was 35.2 months for all patients, 42 months for downstaged patients, 13 months when upstaged, and 17 months for those who remained at the same stage (P=0.08). OS by histological type was 30 months for adenocarcinoma and 71 months for squamous cell carcinoma (P=0.06). Conclusions: NAC was effective in downstaging 59% of patients and effectively increased the chance for an R0 resection. These patients, in turn, had improved OS compared to the median OS. Patients with squamous cell carcinoma showed a trend towards more favorable OS.

Original languageEnglish (US)
Pages (from-to)86-91
Number of pages6
JournalJournal of Gastrointestinal Oncology
Volume5
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Esophagectomy
Chemoradiotherapy
Esophageal Neoplasms
Survival Analysis
Survival
Squamous Cell Carcinoma
Tertiary Healthcare
Platinum
Fluorouracil
Adenocarcinoma
Drug Therapy

Keywords

  • Esophageal cancer
  • Esophagectomy
  • Neoadjuvant chemoradiotherapy (NAC)

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer. / Siddiqui, Faisal A.; Atkins, Katelyn M.; Diggs, Brian S.; Thomas, Charles; Hunter, John; Dolan, James.

In: Journal of Gastrointestinal Oncology, Vol. 5, No. 2, 2014, p. 86-91.

Research output: Contribution to journalArticle

@article{bea72e63cc77427eb86632b836cecab1,
title = "Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer",
abstract = "Background: Patients treated with neoadjuvant chemoradiotherapy (NAC) followed by esophagectomy are more likely to have negative margins at resection, be downstaged, and have improved overall survival (OS). The specific aim of this study was to analyze OS outcomes using NAC followed by esophagectomy at a single, tertiary care academic medical center. Methods: We retrospectively analyzed 106 patients that underwent NAC with platinum-based chemotherapy plus 5-fluorouracil (5-FU) or capecitabine followed by esophagectomy from September 1996 to May 2011. OS was analyzed by the Kaplan Meier method. Results: Initial staging determined that of 106 patients, 62{\%} had stage III (n=66), 31{\%} stage II (n=33), and 7{\%} had stage I disease (n=7). Following NAC, 92.5{\%} (n=98) were resected with negative (R0) margins and pathologic staging revealed 59{\%} (n=62) were downstaged, 9{\%} (n=10) were upstaged, and 32{\%} (n=34) remained at the same stage. A pathologic complete response (pCR) was achieved in 29{\%} (n=31) of the cohort. Median OS was 35.2 months for all patients, 42 months for downstaged patients, 13 months when upstaged, and 17 months for those who remained at the same stage (P=0.08). OS by histological type was 30 months for adenocarcinoma and 71 months for squamous cell carcinoma (P=0.06). Conclusions: NAC was effective in downstaging 59{\%} of patients and effectively increased the chance for an R0 resection. These patients, in turn, had improved OS compared to the median OS. Patients with squamous cell carcinoma showed a trend towards more favorable OS.",
keywords = "Esophageal cancer, Esophagectomy, Neoadjuvant chemoradiotherapy (NAC)",
author = "Siddiqui, {Faisal A.} and Atkins, {Katelyn M.} and Diggs, {Brian S.} and Charles Thomas and John Hunter and James Dolan",
year = "2014",
doi = "10.3978/j.issn.2078-6891.2014.014",
language = "English (US)",
volume = "5",
pages = "86--91",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "2",

}

TY - JOUR

T1 - Overall survival analysis of neoadjuvant chemoradiotherapy and esophagectomy for esophageal cancer

AU - Siddiqui, Faisal A.

AU - Atkins, Katelyn M.

AU - Diggs, Brian S.

AU - Thomas, Charles

AU - Hunter, John

AU - Dolan, James

PY - 2014

Y1 - 2014

N2 - Background: Patients treated with neoadjuvant chemoradiotherapy (NAC) followed by esophagectomy are more likely to have negative margins at resection, be downstaged, and have improved overall survival (OS). The specific aim of this study was to analyze OS outcomes using NAC followed by esophagectomy at a single, tertiary care academic medical center. Methods: We retrospectively analyzed 106 patients that underwent NAC with platinum-based chemotherapy plus 5-fluorouracil (5-FU) or capecitabine followed by esophagectomy from September 1996 to May 2011. OS was analyzed by the Kaplan Meier method. Results: Initial staging determined that of 106 patients, 62% had stage III (n=66), 31% stage II (n=33), and 7% had stage I disease (n=7). Following NAC, 92.5% (n=98) were resected with negative (R0) margins and pathologic staging revealed 59% (n=62) were downstaged, 9% (n=10) were upstaged, and 32% (n=34) remained at the same stage. A pathologic complete response (pCR) was achieved in 29% (n=31) of the cohort. Median OS was 35.2 months for all patients, 42 months for downstaged patients, 13 months when upstaged, and 17 months for those who remained at the same stage (P=0.08). OS by histological type was 30 months for adenocarcinoma and 71 months for squamous cell carcinoma (P=0.06). Conclusions: NAC was effective in downstaging 59% of patients and effectively increased the chance for an R0 resection. These patients, in turn, had improved OS compared to the median OS. Patients with squamous cell carcinoma showed a trend towards more favorable OS.

AB - Background: Patients treated with neoadjuvant chemoradiotherapy (NAC) followed by esophagectomy are more likely to have negative margins at resection, be downstaged, and have improved overall survival (OS). The specific aim of this study was to analyze OS outcomes using NAC followed by esophagectomy at a single, tertiary care academic medical center. Methods: We retrospectively analyzed 106 patients that underwent NAC with platinum-based chemotherapy plus 5-fluorouracil (5-FU) or capecitabine followed by esophagectomy from September 1996 to May 2011. OS was analyzed by the Kaplan Meier method. Results: Initial staging determined that of 106 patients, 62% had stage III (n=66), 31% stage II (n=33), and 7% had stage I disease (n=7). Following NAC, 92.5% (n=98) were resected with negative (R0) margins and pathologic staging revealed 59% (n=62) were downstaged, 9% (n=10) were upstaged, and 32% (n=34) remained at the same stage. A pathologic complete response (pCR) was achieved in 29% (n=31) of the cohort. Median OS was 35.2 months for all patients, 42 months for downstaged patients, 13 months when upstaged, and 17 months for those who remained at the same stage (P=0.08). OS by histological type was 30 months for adenocarcinoma and 71 months for squamous cell carcinoma (P=0.06). Conclusions: NAC was effective in downstaging 59% of patients and effectively increased the chance for an R0 resection. These patients, in turn, had improved OS compared to the median OS. Patients with squamous cell carcinoma showed a trend towards more favorable OS.

KW - Esophageal cancer

KW - Esophagectomy

KW - Neoadjuvant chemoradiotherapy (NAC)

UR - http://www.scopus.com/inward/record.url?scp=84995810412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995810412&partnerID=8YFLogxK

U2 - 10.3978/j.issn.2078-6891.2014.014

DO - 10.3978/j.issn.2078-6891.2014.014

M3 - Article

AN - SCOPUS:84995810412

VL - 5

SP - 86

EP - 91

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 2

ER -